This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Novel mechanisms of carboplatin resistance in epithelial ovarian cancer and their therapeutic potential
DownloadFall 2015
Ovarian cancer is the fifth leading cause of cancer-related mortality in women. Epithelial ovarian cancer (EOC) constitutes approximately 90% of all ovarian malignancies. Platinum-based compounds have been used to treat EOC, with carboplatin currently being used as a first-line therapeutic agent...
-
Fall 2014
Chemoresistance is one of the major hurdles to induce a cure in patients with epithelial ovarian cancer (EOC). RUNX3, belonging to the family of RUNX transcription factors, has been shown to act in an oncogenic manner by promoting proliferation and colony formation when overexpressed, in EOC....
-
Spring 2022
Ovarian cancer is the most lethal gynecological cancer, and epithelial ovarian cancer (EOC) accounts for about 90% of ovarian cancers. Despite advancements in medical technology, the overall survival rate of EOC has improved only slightly, with a 5-year survival rate of less than 50%. One cause...